See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Artificial Intelligence
Social Media
Sanctions
Inflation
European Union
US Economy
Republican Party
Education
Natural Disasters
Stock Markets
Immigration
Published • loading... • Updated

XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001

Summary by Clinical Trials Arena
XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.The post XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001 appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Clinical Trials ArenaClinical Trials Arena

XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.The post XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001 appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Friday, July 11, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal